エピソード

  • Chronic Lymphocytic Leukemia (CLL): Review of Combination Approaches

    Chronic Lymphocytic Leukemia (CLL): Review of Combination Approaches
    2026/02/23

    Transforming CLL care: measurable residual disease (MRD) guided stopping, smart triplet selection, and next‑gen Bruton tyrosine kinase (BTKs)—practical insights.

    Credit available for this activity expires: 02/19/27

    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    23 分
  • Quick Talk on ES-SCLC: What Community Clinicians Need to Know Now

    Quick Talk on ES-SCLC: What Community Clinicians Need to Know Now
    2026/02/20

    Are you up to date on the management of extensive-stage small cell lung cancer (ES-SCLC)?

    Credit available for this activity expires: 2/20/27
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/quick-talk-es-sclc-what-community-clinicians-need-know-now-2026a100055m?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    20 分
  • Best Practices for Integrating Biosimilars Into Clinical Practice: An Interprofessional Perspective

    Best Practices for Integrating Biosimilars Into Clinical Practice: An Interprofessional Perspective
    2026/02/20

    Clear communication builds trust in biosimilars.

    Credit available for this activity expires: 2/19/27
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003245?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    30 分
  • CAR T Cells in SLE: A New Frontier in Autoimmunity

    CAR T Cells in SLE: A New Frontier in Autoimmunity
    2026/02/12

    Early evidence for CAR T-cell therapy in lupus is compelling. Are you up-to-date?

    Credit available for this activity expires: 2/9/26
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/car-t-cells-sle-new-frontier-autoimmunity-2026a10003ow?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    34 分
  • Case by Case: Managing ES-SCLC in the Real World Through Patient Partnership

    Case by Case: Managing ES-SCLC in the Real World Through Patient Partnership
    2026/02/11

    Are you up to date with the latest management for extensive-stage small cell lung cancer?

    Credit available for this activity expires: 2/11/27
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/case-case-managing-es-sclc-real-world-through-patient-2026a10003ro?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    43 分
  • Utilizing Automated Insulin Delivery to Close Gaps in Type 2 Diabetes Care

    Utilizing Automated Insulin Delivery to Close Gaps in Type 2 Diabetes Care
    2026/02/03

    How can AID close gaps in T2D care and help you personalize evidence-based AID for real-world practice?

    Credit available for this activity expires: 1/30/27
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/utilizing-automated-insulin-delivery-close-gaps-type-2-2026a10002xh?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    23 分
  • Empowering Choices in Moderate to Severe Asthma: Partnering With Patients for Optimal Treatment Decisions

    Empowering Choices in Moderate to Severe Asthma: Partnering With Patients for Optimal Treatment Decisions
    2026/01/30

    Shared decision-making isn't just a buzzword—it's the key to better adherence, fewer exacerbations, and improved quality of life for your patients.

    Credit available for this activity expires: [01/30/27]
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/empowering-choices-moderate-severe-asthma-partnering-2026a10001d4?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    34 分
  • Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data

    Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data
    2026/01/29

    Did you know that as MBC patients get treated with multiple lines of ET, the percentage of patients who develop an ESR1 mutation increases?

    Credit available for this activity expires: 1/26/27
    Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/current-and-future-oral-serd-strategies-management-er-2026a100022b?ecd=bdc_podcast_libsyn_mscpedu
    続きを読む 一部表示
    29 分